Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29059744 | 0.80 | ALDH1A1 (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15974748 | 0.79 | FFAR1 (0.46) | CYP2C19FFAR1 | |
| SCHEMBL15974749 | 0.79 | FFAR1 (0.46) | CYP2C19FFAR1 | |
| SCHEMBL2591240 | 0.79 | ALDH1A1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7827997 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4MAPK1MAPTKDM4E | |
| SCHEMBL29085806 | 0.78 | MEN1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30062565 | 0.77 | AOC3 (0.51) | CA1CA2CA7CA9AOC3 | |
| SCHEMBL17841325 | 0.77 | AOC3 (0.51) | CA1CA2CA7CA9AOC3 | |
| SCHEMBL18253186 | 0.77 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8025197 | 0.76 | AOC3 (0.43) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362338-A | Method for preparing 3, 3-diaryl allyl substituted organic phosphonate compound | 湖南理工学院 | 2024-01-09 | — | — | CN | claimed |
| CN-113548965-B | Preparation method of 1,4 eneyne compound | 南京工业大学 | 2022-07-26 | — | — | CN | claimed |
| CN-113548965-A | Preparation method of 1, 4-eneyne compound | 南京工业大学 | 2021-10-26 | — | — | CN | claimed |
| US-20260118258-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE | BIOS THERAPY PHYSIOLOGICAL SYSTEMS FOR HEALTH S P A (IT) | 2026-04-30 | — | — | US | disclosed |
| US-12546707-B2 | Validation of natural matrices for therapeutic use | Bios-Therapy, PhysiologicalSystems for Health S.p.A. (IT) | 2026-02-10 | — | — | US | disclosed |
| US-20250383343-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-12-18 | — | — | US | disclosed |
| US-20250383340-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-12-18 | — | — | US | disclosed |
| US-20250383341-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-12-18 | — | — | US | disclosed |
| US-20250231101-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE ON HUMANS, ANIMALS AND PLANTS ON BIO-PHYSICAL BASES AS AN ALTERNATIVE TO VALIDATION THROUGH CHEMICALLY DEFINABLE SUBSTANCES DERIVED FROM SAID MATRICES BY ISOLATION AND/OR SYNTHESIS PROCESSES AND ALSO AS AN ALTERNATIVE TO PRODUCTS COMPRISING NATURAL MATRICES VALIDATED ON THE BASIS OF THEIR TRADITIONAL USE | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-07-17 | — | — | US | disclosed |
| WO-2025149788-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-07-17 | — | — | WO | disclosed |
| US-20240317660-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY PHENYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2024-09-26 | — | — | US | disclosed |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| WO-2005095629-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS BY MEANS OF AZEOTROPICALLY DRIED ENZYME COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005014509-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM IP ASSETS B.V. (NL) | 2005-02-17 | — | — | WO | disclosed |
| US-6841691-B2 | Process for the preparation of enantiomerically enriched esters and alcohols | DSM N.V. (NL) | 2005-01-11 | — | — | US | disclosed |
| US-20040077059-A1 | Process for the preparation of enantiomerically enriched esters and alcohols | DSM IP ASSETS B.V. (NL) | 2004-04-22 | — | — | US | disclosed |
| EP-1283898-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM N.V. (NL) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090396-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ESTERS AND ALCOHOLS | DSM N.V. (NL) | 2001-11-29 | — | — | WO | disclosed |
| US-4014899-A | ANTIASTHMATIC AND ANTIALLERGIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3973030-A | Antiasthmatic 5,6-benzoisoindoline compositions | CIBA-GEIGY CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317660-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY PHENYL COMPOUNDS | ADH1A, AHR, ADH1C | CA1 2124/4885CA2 3452/4885CA12 3494/4885 |
| US-12546707-B2 | Validation of natural matrices for therapeutic use | COL2A1, IL1B, COL1A1 | CA1 636/4885CA2 1158/4885CA12 508/4885 |
| US-20260118258-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE | SOST, FABP4, COL2A1 | CA1 4754/4885CA2 4712/4885CA12 4474/4885 |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | ALDH3A1, NQO1, DERA | CA1 1449/4885CA2 1014/4885CA12 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.